{"publication_id":"06888b97-d174-4ea3-8963-a9e4112d22e8","content_hash":"sha256:d7bbb44a816b926104ae7c49e0a6e547dddd39ab07f5456a4203c34eb747b8e6","nodes":[{"id":"06888b97-d174-4ea3-8963-a9e4112d22e8","type":"publication","title":"Alpha memo: nicotinamide riboside exercise performance"},{"id":"claim_1","type":"claim","text":"Receipt 1:** \"The NAD+ precursor nicotinamide riboside decreases exercise performance in rats\" (2016) — Chronic 21-day NR administration at 300 mg/kg/day in young Wistar rats showed a tendency toward worse swimming performance versus saline controls."},{"id":"claim_2","type":"claim","text":"Receipt 2:** \"Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study\" (2020) — Acute NR supplementation in older men (who exhibited lower erythrocyte NAD(P)H and higher urine F₂-isoprostanes at baseline) increased NAD(P)H levels, decreased oxidative stress, and improved VO₂-related performance, while no comparable benefit appeared in young subjects."},{"id":"claim_3","type":"claim","text":"Why this is surprising:** Receipt 1 made plausible the expectation that chronic NR would uniformly impair exercise output, yet Receipt 2 shows the same anchor can flip toward ergogenic benefit when baseline redox status is deficient, suggesting age-dependent reversal rather than a stable directional effect."},{"id":"source_1","type":"source","study":"The NAD + precursor nicotinamide riboside decreases exercise performance in rats","year":2016,"doi":"10.1186/s12970-016-0143-x","url":"https://doi.org/10.1186/s12970-016-0143-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study.","year":2020,"doi":"10.1007/s00394-019-01919-4","url":"https://doi.org/10.1007/s00394-019-01919-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"06888b97-d174-4ea3-8963-a9e4112d22e8","to":"claim_1","type":"contains_claim"},{"from":"06888b97-d174-4ea3-8963-a9e4112d22e8","to":"claim_2","type":"contains_claim"},{"from":"06888b97-d174-4ea3-8963-a9e4112d22e8","to":"claim_3","type":"contains_claim"}],"screening":{"identified":2,"screened":2,"excluded":0,"included":2,"included_or_retained":2,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"2 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}